FindTrial
Sign In

Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain

Clinical Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism- Related Orofacial Pain: A Randomized Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07109882
Enrollment
60
Registered
2025-08-07
Start date
2025-07-22
Completion date
2025-08-30
Last updated
2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orofacial Pain, Bruxism

Brief summary

To evaluate the clinical effectiveness of chlorzoxazone in comparison to orphenadrine Citrate in relieving the orofacial pain in bruxers. Subjects and Methods: 60 patients above 15-years old complaining of orofacial and temporomandibular disorder/pain, with no history of chronic systemic illness, will be recruited. Patients will randomly be allocated into two groups (n=30): the first group will receive Relaxon (chlorzoxazone) twice daily for two weeks, while the second group will receive Norgesic (orphenadrine Citrate) twice daily for two weeks as well. Pain severity will be assessed by Visual Analogue Scale (VAS) at day 0, 7, and day 14. In addition, a temporomandibular joint (TMJ) evaluation form will be utilized to assess the TMJ parameters before and after initiation of the treatment protocol, i.e at 0 and 14 days. Non parametric statistical analysis will be conducted to explain the results using SPSS V29.

Interventions

DRUGChlorzoxazone

This group will receive Chlorzoxazone twice daily for two weeks

DRUGOrphenadrine Citrate

This group will receive Orphenadrine Citrate twice daily for two weeks.

Sponsors

University of Baghdad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients aged above 15 years-old complaining of orofacial and temporomandibular disorder/pain. * Patients with no history of chronic systemic illness.

Exclusion criteria

* Patients with orofacial injuries. * Patients with head injuries. * Patients Taking analgesics for the last 14 days.

Design outcomes

Primary

MeasureTime frame
Change From Baseline in Orofacial Pain Score in Bruxism Patients (n=30) as Measured by the Visual Analog Scale (VAS) in retaliation to adverse effect of each drug used.From enrollment to the end of treatment at 2 weeks

Countries

Iraq

Contacts

Primary ContactNoor R. Al-Hasani, PhD
noor.raouf@codental.uobaghdad.edu.iq009647732977290

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026